ANJARIUM BIOSCIENCES
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address a range of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach.
ANJARIUM BIOSCIENCES
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.anjarium.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
55.5 M CHF
Technology used in webpage:
Viewport Meta Google Font API Google Tag Manager Google Analytics Google Maps Content Delivery Network Amazon Global Site Tag HSTS Organization Schema
Similar Organizations
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
ARTHEx Biotech
AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.
BerGenBio
BerGenBio is clinical-stage biopharma developing first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
GlycoEra
GlycoEra is a CustomGlycanengineering platform that unlocks the glycan-mediated biology to develop a pipeline of novel therapeutics.
Imcyse
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Ribbon Biolabs
Ribbon Biolabs defines new standards for molecular biology by applying innovative methods for DNA synthesis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Omega Funds
Omega Funds investment in Series A - Anjarium Biosciences
Abingworth
Abingworth investment in Series A - Anjarium Biosciences
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Anjarium Biosciences
Gimv
Gimv investment in Series A - Anjarium Biosciences
Surveyor Capital
Surveyor Capital investment in Series A - Anjarium Biosciences
Swiss Federal Commission for Innovation and Technology
Swiss Federal Commission for Innovation and Technology investment in Grant - Anjarium Biosciences
Key Employee Changes
Official Site Inspections
http://www.anjarium.com Semrush global rank: 9.99 M Semrush visits lastest month: 286
- Host name: 199.60.103.74
- IP address: 199.60.103.74
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Anjarium Biosciences"
Accelerate Genetic Medicine Discovery | Anjarium Biosciences
Anjarium Biosciences accelerates genetic medicine development with innovative DNA technology, customizable constructs, and advanced therapies.See details»
Anjarium Biosciences - Crunchbase Company Profile & Funding
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.See details»
Anjarium Biosciences 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Anjarium Biosciences. Use the PitchBook Platform to explore the full profile.See details»
Anjarium Biosciences - Funding, Financials, Valuation & Investors
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.See details»
Anjarium Biosciences - Contacts, Employees, Board Members, …
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.See details»
Anjarium Biosciences appoints Stephen Yoo, MD as Chief …
Jun 14, 2022 Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announced the appointment of …See details»
Anjarium Biosciences Company Profile - Craft
Anjarium Biosciences has 5 employees at their 1 location and $61 m in total funding,. See insights on Anjarium Biosciences including office locations, competitors, revenue, financials, …See details»
Anjarium Biosciences (Switzerland) Funding: $61M
Mar 11, 2025 Pioneering the next generation of non-viral gene therapy. Viral vectors have enabled early successes in the gene therapy space, but their immunogenicity, limited payload …See details»
Anjarium Biosciences - 2025 Company Profile - Tracxn
Mar 5, 2025 Anjarium Biosciences - Developer of next generation non-viral gene therapies. Raised a total funding of $60.4M over 1 round from 5 investors.See details»
Anjarium Biosciences AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Anjarium Biosciences AG of Schlieren, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
Anjarium Locations - Contract Research Map
Anjarium’s novel, cell-free, enzymatic approach for producing linear, double-stranded DNA offers significant advantages to customers seeking faster alternatives, more complex constructs, and …See details»
Anjarium Biosciences - Raised $60.4M Funding from 5 investors
Mar 5, 2025 Anjarium Biosciences has raised a total funding of $60.4M over 1 round from 5 investors. Investors include Abingworth, Omega Funds and 3 others. Their latest funding …See details»
Anjarium Biosciences AG - startup.ch
Anjarium Biosciences AG: Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. …See details»
Anjarium Biosciences - Updates, News, Events, Signals & Triggers
Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.See details»
Anjarium Biosciences’ CEO on its next-gen gene therapies
Jul 15, 2022 Among those generating buzz is Switzerland-based Anjarium Biosciences, who crowned Stephen Yoo as its new CEO in June. Drawing on his medical training and extensive …See details»
Anjarium Biosciences raises CHF 55.5M to develop non-viral gene ...
Sep 16, 2021 Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies today announced the closing of a …See details»
Anjarium Anjarium Anjarium - Gimv
Anjarium Biosciences AG is a cell and gene therapy tools and technology company based in Switzerland and the U.S. Anjarium is capable of designing, manufacturing, and supplying …See details»
Anjarium Raises $61 Million to Develop Next-Generation Non-viral …
Sep 16, 2021 Swiss biotech Anjarium Biosciences raised $61 million (CHF55.5M) in a series A financing round to advance development of a new class of non-viral gene therapies to deliver …See details»
Joel de Beer (Anjarium Biosciences AG) - life-sciences-europe.com
Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren. …See details»
Anjarium: a hybrid approach to non-viral gene therapy
Sep 16, 2021 Switzerland-based Anjarium believes its platform using lipid nanoparticles and extracellular vesicles can help create non-viral gene therapies that can find a niche in the …See details»